ClinicalTrials.Veeva

Menu

Comparison of the Effectiveness of Thoracolumbar Fascia Mobilization and Ultrasound-Guided Thoracolumbar Interfascial 5% Dextrose Injection in Patients With Chronic Low Back Pain

A

Ankara City Hospital

Status

Enrolling

Conditions

Chronic Low Back Pain

Treatments

Drug: 5% Dextrose
Procedure: Myofascial Release

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The aim of this study is to investigate the effects of thoracolumbar fascia mobilization and ultrasound-guided thoracolumbar interfascial 5% dextrose injection on pain, range of motion, disability, quality of life, proprioception, and fascial thickness and echogenicity in patients with nonspecific chronic low back pain.

-Primary Objective: The primary objective is to evaluate the effects of these interventions on pain, functional status and range of motion.

-Secondary Objective: The secondary objective is to assess the long-term effects on quality of life, proprioception, fascial thickness, and echogenicity.

Enrollment

75 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Male or female patients aged 18 to 65 years
  2. Presence of low back pain lasting longer than 3 months
  3. No adequate response to medical treatment
  4. Voluntary participation in the study

Exclusion criteria

  1. Age below 18 or above 65 years
  2. Body mass index (BMI) greater than 30 kg/m²
  3. Pregnancy or breastfeeding
  4. Presence of coagulation disorders
  5. History of spinal surgery
  6. Presence of inflammatory or malignant diseases
  7. Local infection at the spine or injection site
  8. Presence of lumbar disc pathology causing radiculopathy
  9. Presence of spinal stenosis, spondylolysis, or spondylolisthesis
  10. Participation in physical therapy or any manual therapy within the past 6 months
  11. Receiving lumbar injections within the past 6 months
  12. History of allergy to injection materials
  13. Refusal to participate in the study

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

75 participants in 3 patient groups

Thoracolumbar Fascia Mobilization Group
Active Comparator group
Description:
Patients in this group will receive thoracolumbar fascia mobilization. A total of six sessions of myofascial release therapy will be administered twice per week for three weeks.
Treatment:
Procedure: Myofascial Release
Thoracolumbar Interfascial 5% Dextrose Injection Group
Active Comparator group
Description:
Patients in this group will receive ultrasound-guided thoracolumbar interfascial 5% dextrose injection. After being informed about the procedure, the patient will be placed in the prone position on the examination table, with a small pillow placed under the abdomen to allow relaxation of the lumbar muscles. Axial scanning will be performed using a Logiq 9 (GE Medical Systems®) ultrasound device equipped with a linear probe (7-12 MHz, "ZONARE"), and the probe will be positioned at the level of the L3 spinous process. The multifidus, longissimus, and iliocostalis muscles will be visualized. A 21-gauge (0.80 × 38 mm) needle will then be inserted from lateral to medial into the interfascial plane of the posterior layer of the thoracolumbar fascia using an in-plane technique. After confirming negative aspiration (to rule out vascular puncture), 10 mL of 5% dextrose solution will be injected into the target area.
Treatment:
Drug: 5% Dextrose
Combined Therapy Group
Active Comparator group
Description:
Patients in this group will receive both myofascial release therapy and ultrasound-guided thoracolumbar interfascial 5% dextrose injection as described above.
Treatment:
Procedure: Myofascial Release
Drug: 5% Dextrose

Trial contacts and locations

1

Loading...

Central trial contact

Büşra ALÇIN, Medical Doctor; Barış NACIR, Professor Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems